Cellular Adaptations — Hypertrophy, Hyperplasia, Atrophy, Metaplasia

Hypertrophy — Increase in Cell Size

• Increased protein synthesis and organelle production: Cells enlarge through accumulation of additional cytoplasm, organelles (mitochondria, rough endoplasmic reticulum), and structural proteins. This occurs via activation of mTOR signaling and IGF-1 pathways, which upregulate ribosomal protein synthesis and reduce protein degradation. The cell maintains normal nuclear-to-cytoplasmic ratio initially but eventually becomes hypertrophied with increased cell volume without cell division.

• Enhanced metabolic demand and functional capacity: Hypertrophied cells demonstrate increased metabolic activity, greater numbers of contractile proteins (in cardiac/skeletal muscle), or amplified secretory machinery (in endocrine cells). Gene expression is altered to support the hypertrophic phenotype; in cardiac hypertrophy, fetal gene programs are reactivated (reexpression of ANP, BNP, β-myosin heavy chain). The hypertrophied cell is functionally competent but energetically expensive.

• Growth factor and mechanical signal transduction: Mechanical stretch (in cardiac myocytes), hormonal stimulation (catecholamines, angiotensin II), and cytokine signaling (TNF-α, IL-6) activate MAPK cascades (ERK1/2), calcineurin-NFAT pathways, and JAK-STAT signaling. These converge on transcription factors that promote expression of growth-related genes. In skeletal muscle, mechanical loading activates Akt/mTOR and AMPK pathways.

Hyperplasia — Increase in Cell Number

• Increased cell division and proliferation: Hyperplasia results from enhanced mitotic activity driven by growth factors, hormones, or chronic antigenic stimulation. The G1/S checkpoint is overridden through upregulation of cyclins and cyclin-dependent kinases; p53 and Rb pathways remain functionally intact, distinguishing hyperplasia from dysplasia. Cell cycle progression is accelerated but remains responsive to anti-proliferative signals.

• Sustained growth factor signaling: Chronic stimulation by estrogen (in breast and endometrial tissue), prolactin (in mammary glands), androgens (in prostate), or inflammatory cytokines (IL-6, TNF-α) maintains proliferative signals. In immune hyperplasia, antigen-driven B and T cell expansion occurs through TCR/BCR signaling, IL-2, and co-stimulatory molecule engagement.

• Shortened G0/G1 phase and increased stem cell activation: Hyperplastic tissues show increased recruitment of progenitor and stem cells from resting pools. Niche signaling (Wnt, Notch, Hedgehog) is upregulated, promoting asymmetric division and differentiation. The hyperplastic tissue maintains organized architecture and normal maturation—a critical distinction from dysplasia.

Atrophy — Decrease in Cell Size and Mass

• Protein degradation exceeding protein synthesis: Atrophy results from net loss of cytoplasmic protein through activation of ubiquitin-proteasome pathway and autophagy-lysosomal degradation. Forkhead box proteins (FoxO), particularly FoxO3, are upregulated and induce expression of E3 ubiquitin ligases (MuRF1, MAFbx). Cellular ATP depletion favors autophagic flux; lysosomes accumulate and may contain lipofuscin (age pigment).

• Reduced growth signaling and mitochondrial dysfunction: Withdrawal of growth factors (IGF-1, testosterone) or mechanical stimulation silences mTOR and Akt signaling. Mitochondrial mass decreases; oxidative capacity diminishes. In disuse atrophy, reduced contractile activity downregulates calcium signaling and calcineurin-dependent transcription.

• Selective preservation of essential structures: Atrophied cells maintain metabolic viability and can theoretically recover if the stimulus is reversed. Nuclear size decreases proportionally to cytoplasmic loss (nuclear-to-cytoplasmic ratio remains relatively preserved). Connective tissue fibrosis may occur concurrently, particularly in chronic atrophy.

Metaplasia — Reversible Replacement of One Differentiated Cell Type with Another

• Stem/progenitor cell plasticity and altered differentiation signals: Metaplasia occurs through reprogramming of multipotent stem cells or transdifferentiation of established cells in response to altered environmental signals. The new cell type is better adapted to the altered conditions but typically represents a "lower" level of specialization. Altered expression of transcription factors (CDX2 in intestinal metaplasia, PAX5 suppression, and myeloid factors in transdifferentiation) redirects differentiation pathways.

• Environmental and inflammatory signals driving phenotypic switch: Chronic irritation (smoking, GERD), chronic inflammation (H. pylori), or altered pH and bile exposure activate signaling cascades that suppress normal transcription factor programs and activate ectopic programs. NF-κB and STAT3 often mediate this response to chronic injury. For example, stratified squamous epithelium in the esophagus may be replaced by columnar intestinal-type epithelium (Barrett esophagus) in response to chronic acid exposure and inflammation.

• Reversibility contingent on continued stimulus presence: The metaplastic cells are stable and self-renewing as long as the inciting stimulus persists. Upon removal of the stimulus (e.g., successful H. pylori eradication), metaplastic tissue may revert to original epithelium, though reversion is often incomplete. Critically, metaplasia does not confer malignant potential inherently, but metaplastic tissues are frequently sites of carcinogenesis if the chronic stimulus continues.

HYPERTROPHY

• Increased functional demand: Cardiac hypertrophy from systemic hypertension, aortic stenosis, or athletic training ("athlete's heart"); skeletal muscle hypertrophy from resistance exercise; smooth muscle hypertrophy of bladder from chronic outlet obstruction (BPH, strictures).

• Hormone and growth factor stimulation: Thyroid follicular cell hypertrophy from TSH overstimulation in iodine deficiency; adrenal cortical cell hypertrophy from ACTH; growth hormone and IGF-1 in gigantism/acromegaly; anabolic steroid use in athletes.

• Mechanical stretch and load: Ventricular hypertrophy from hypertension or aortic stenosis; uterine smooth muscle hypertrophy in pregnancy; pyloric sphincter hypertrophy from gastric outlet obstruction.

HYPERPLASIA

• Hormonal stimulation: Endometrial hyperplasia from unopposed estrogen; benign prostatic hyperplasia (BPH) from DHT and aging; breast hyperplasia from estrogen; adrenal cortical hyperplasia from ACTH (congenital or tumor-driven).

• Chronic inflammation and antigenic stimulation: Lymphoid hyperplasia in gut from chronic infection or celiac disease; thyroid hyperplasia from TSH in Graves disease or iodine deficiency; gastric mucosa hyperplasia from H. pylori or hypergastrinemia.

• Compensatory hyperplasia: Hepatic hyperplasia following partial hepatectomy; renal hyperplasia after unilateral nephrectomy; intestinal crypt hyperplasia following villous atrophy.

ATROPHY

• Disuse and denervation: Skeletal muscle atrophy from immobilization, spinal cord injury, or motor neuron disease; bone atrophy from weightlessness or immobilization; neurogenic atrophy with grouped fiber loss and target fibers.

• Reduced blood supply: Cerebral atrophy from chronic ischemia or vascular insufficiency; myocardial atrophy in chronic severe anemia or hypoxia; organ atrophy from vascular occlusion.

• Chronic malnutrition and aging: Generalized tissue atrophy in cachexia, starvation, or chronic disease; age-related sarcopenia; thymic involution with advancing age.

• Chronic disease and endocrine deficiency: Adrenal atrophy from chronic corticosteroid suppression; thyroid atrophy from iodine excess; gonadal atrophy from hypogonadism or testosterone deficiency.

METAPLASIA

• Chronic irritation and inflammation: Barrett esophagus from chronic GERD; intestinal metaplasia of gastric mucosa from chronic H. pylori; squamous metaplasia of respiratory epithelium from smoking; bladder intestinal metaplasia from chronic irritation (schistosomiasis).

• Vitamin A deficiency: Squamous metaplasia of respiratory, urinary, and lacrimal epithelium; loss of normal ciliated columnar epithelium; increased infection risk.

• Chronic obstruction and altered mechanical/chemical environment: Bile duct metaplasia; altered pH and microbial flora promoting intestinalization.

HYPERTROPHY

• Cardiac hypertrophy: Dyspnea on exertion, reduced exercise tolerance, palpitations; signs of diastolic dysfunction (S4 gallop, elevated JVP); eventual progression to heart failure with reduced ejection fraction or preserved ejection fraction depending on type and stage.

• Smooth muscle hypertrophy (BPH): Lower urinary tract symptoms—nocturia, urinary frequency, hesitancy, weak stream, incomplete emptying; elevated post-void residual; palpable, enlarged, boggy prostate on digital rectal exam.

• Skeletal muscle hypertrophy: Increased muscle bulk and strength; normal muscle function and normal serum CK; normal electromyography.

HYPERPLASIA

• Endometrial hyperplasia: Abnormal uterine bleeding, often heavy and prolonged; increased risk of progression to carcinoma, particularly in atypical hyperplasia; vaginal bleeding in postmenopausal women is concerning.

• Benign prostatic hyperplasia: Lower urinary tract symptoms similar to smooth muscle hypertrophy; elevated serum PSA (though less specific); increased urinary hesitancy and nocturia; digital rectal exam shows large, boggy prostate.

• Thyroid hyperplasia (Graves disease or iodine deficiency): Diffuse goiter (often with bruit); hyperthyroid symptoms (Graves) or euthyroid goiter (iodine deficiency); elevated free T4 and suppressed TSH (Graves); low-normal or elevated TSH (endemic goiter).

ATROPHY

• Neurogenic skeletal muscle atrophy: Generalized weakness; muscle wasting and visible fasciculations; diminished deep tendon reflexes; elevated serum CK if acute denervation; EMG shows denervation potentials and reinnervation attempts.

• Cerebral atrophy: Cognitive decline, dementia, gait instability; widened sulci and enlarged ventricles on imaging; progressive neurodegeneration.

• Cardiac atrophy: Heart failure with reduced ejection fraction; decreased cardiac output; dilated heart on imaging despite reduced overall size.

METAPLASIA

• Barrett esophagus: Often asymptomatic or associated with chronic GERD symptoms; no specific clinical findings; diagnosed on endoscopy with biopsy showing intestinal-type columnar epithelium; increased risk of esophageal adenocarcinoma.

• Squamous metaplasia of respiratory tract (smoking): Chronic cough, sputum production; increased susceptibility to infection due to loss of ciliary clearance; increased lung cancer risk.

• Vitamin A deficiency-related metaplasia: Night blindness, xerophthalmia, Bitot spots on conjunctiva; squamous metaplasia of respiratory, lacrimal, and urinary epithelium; increased infection risk and corneal scarring.

HYPERTROPHY

• Histological findings: Enlarged individual cells with increased cytoplasmic volume and normal nuclear-to-cytoplasmic ratio; increased numbers of mitochondria and organelles on electron microscopy; preserved tissue architecture and normal cellularity (number of cells unchanged).

• Cardiac hypertrophy: Increased myocyte diameter (>20 µm); myocyte nuclear enlargement; increased interstitial fibrosis may develop; concentric pattern with increased wall thickness relative to chamber diameter (pressure overload, e.g., hypertension) versus eccentric pattern with chamber dilation (volume overload, e.g., mitral regurgitation).

• Gross pathology: Enlarged organ (heart may weigh >500 g); increased muscle mass with preserved normal color; no necrosis or fibrosis in compensated hypertrophy.

• Imaging: Echocardiography shows increased ventricular wall thickness, reduced diastolic function, increased left ventricular mass; cardiac MRI demonstrates hypertrophied myocardium with normal or increased ejection fraction initially.

• Lab values: Elevated BNP/NT-proBNP in decompensated cardiac hypertrophy; normal troponin unless acute decompensation; normal or elevated CK in skeletal muscle hypertrophy.

HYPERPLASIA

• Histological findings: Increased number of normal-appearing cells; preserved maturation and differentiation; intact tissue architecture (organized glandular or follicular structures); increased mitotic figures but normal mitotic index and no abnormal mitoses; no atypia or dysplasia.

• Endometrial hyperplasia grading (FIGO 2014): Simple hyperplasia (normal glandular architecture, increased glands/stroma ratio); complex hyperplasia (crowded glands, minimal intervening stroma); atypia presence/absence (nuclear enlargement, irregular nuclear membranes, coarse chromatin in atypical forms). Progression risk: simple 1%, complex 3%, atypical simple 8%, atypical complex 29%.

• Gross pathology: Tissue appears thickened or enlarged; texture remains normal; no mass lesions (unless early dysplasia develops).

• Lab/Imaging: Elevated hormone levels (estrogen in endometrial hyperplasia, PSA in BPH, TSH in thyroid hyperplasia); imaging shows organ enlargement without focal masses.

ATROPHY

• Histological findings: Reduced cell size with proportionally reduced cytoplasm; nuclear size reduction proportional to cytoplasmic loss; increased lipofuscin deposition (golden-brown, non-refractile pigment); enhanced collagen deposition and fibrosis in chronic atrophy; preserved basic tissue architecture though overall tissue volume reduced.

• Skeletal muscle atrophy specifics: Grouped atrophy in neurogenic causes (entire motor unit atrophies together); scattered atrophy in disuse; target fibers (central pallor on oxidative stains) in neurogenic denervation and reinnervation.

• Gross pathology: Organ size reduced; pale appearance; increased connective tissue relative to parenchyma; flabby consistency.

• Imaging: Reduced organ size on CT/MRI; loss of normal tissue planes; fatty infiltration in chronic atrophy (particularly muscle).

METAPLASIA

• Histological findings: Replacement of original epithelial type with another mature, differentiated epithelium; absence of dysplasia or atypia (distinguishes from dysplasia); intact basement membrane and organized architecture with appropriate maturation; goblet cells and columnar mucosa in intestinal metaplasia; keratinization in squamous metaplasia.

• Barrett esophagus specifics: Columnar-lined esophagus (normally stratified squamous); specialized intestinal metaplasia with goblet cells (most specific finding); may also see gastric cardiac or fundic type mucosa. Dysplasia grading essential: negative for dysplasia, indefinite for dysplasia, low-grade

Immediate stabilisation (adaptation that has decompensated)

• Acute urinary retention from BPH: immediate urethral (or suprapubic) catheter decompression, then start medical therapy before a trial of void — the AUA BPH guideline treats retention as an urgent, not elective, problem.
• Infantile hypertrophic pyloric stenosis: this is a medical emergency and a surgical elective procedure — correct the hypochloremic, hypokalemic metabolic alkalosis with isotonic saline plus potassium first; pyloromyotomy only after electrolytes normalise.
• Adrenal atrophy from chronic exogenous glucocorticoids: stress-dose hydrocortisone if the patient presents hypotensive; never stop steroids abruptly.

Remove or block the driving stimulus (first line)

• Antisecretory therapy: a proton pump inhibitor (omeprazole) for Barrett esophagus per the ACG Barrett/GERD guidelines — controls reflux and symptoms, though it does not reliably reverse the metaplasia.
• Antihypertensives: ACC/AHA hypertension guideline agents (ACE inhibitor/ARB, thiazide-type diuretic, dihydropyridine CCB) regress left ventricular hypertrophy by unloading the ventricle.
• Alpha-1 blockers (tamsulosin) for symptom relief and 5-alpha-reductase inhibitors (finasteride) to shrink glandular volume in BPH (AUA); combination for large glands.
• Progestin therapy (levonorgestrel intrauterine system or oral megestrol) for endometrial hyperplasia without atypia, per ACOG/SGO.
• H. pylori eradication with optimized bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole, 14 days) as preferred first-line per ACG; clarithromycin-containing regimens only when susceptibility testing confirms macrolide sensitivity and there is no prior macrolide exposure. Confirm eradication with urea breath test, stool antigen, or biopsy ≥4 weeks after therapy.
• Tobacco cessation (USPSTF: behavioural counselling plus varenicline or nicotine replacement) — bronchial squamous metaplasia may partially regress after cessation, though risk does not return to that of a never-smoker.
• Vitamin A repletion for keratinising metaplasia of respiratory/ocular epithelium.

Definitive/procedural

• Endoscopic eradication therapy (radiofrequency ablation ± endoscopic mucosal resection) for Barrett with dysplasia (ACG); surveillance only for non-dysplastic disease.
• Hysterectomy for atypical hyperplasia/endometrial intraepithelial neoplasia (ACOG).
• TURP for refractory BPH; aortic valve replacement for severe symptomatic aortic stenosis (ACC/AHA valvular guideline).

Contraindicated

• Unopposed estrogen in a woman with an intact uterus.
• ACE inhibitors/ARBs in pregnancy — all are contraindicated; captopril's short half-life makes it a titration drug, not a pregnancy drug.
• Treating physiologic adaptation (athlete's heart, pregnancy uterus).

Hypertrophy

• Subendocardial ischemia: myocyte mass outgrows its capillary supply and coronary flow reserve falls — angina with angiographically normal coronaries, exertional dyspnea, ischemic ST changes.
• Diastolic dysfunction progressing to heart failure: interstitial fibrosis stiffens the ventricle — S4 gallop, elevated NT-proBNP, HFpEF; late transition to a dilated, failing ventricle (HFrEF), which requires the four guideline-directed classes per ACC/AHA/HFSA: ARNI (or ACEI/ARB), beta blocker, MRA, and SGLT2 inhibitor.
• Atrial fibrillation and sudden cardiac death: atrial stretch and fibrotic re-entry circuits; ventricular fibrillation/pulseless VT in this setting is a shockable-rhythm cardiac arrest — an immediate emergency.
• Obstructive uropathy: bladder detrusor hypertrophy eventually decompensates — rising post-void residual, hydronephrosis, post-renal AKI; bilateral hydronephrosis with AKI is an emergency.

Hyperplasia

• Malignant transformation: pathologic hyperplasia under sustained trophic stimulation is fertile soil for dysplasia — atypical endometrial hyperplasia carries the highest progression risk to endometrioid carcinoma; new postmenopausal bleeding demands sampling.
• Hemorrhage/anemia: prolonged heavy uterine bleeding causing symptomatic iron-deficiency anemia.

Atrophy

• Adrenal crisis: HPA-axis suppression atrophies the zona fasciculata; abrupt steroid withdrawal or intercurrent illness produces hypotension, hyponatremia, hypoglycemia — a true emergency treated with IV hydrocortisone and fluids before confirmatory testing.
• Sarcopenia and disuse sequelae: falls, contractures, pressure injury, immobility-associated VTE.
• Brown atrophy: lipofuscin accumulation in a shrunken heart or liver of a cachectic patient — a marker, not itself harmful.

Metaplasia

• Adenocarcinoma of the distal esophagus from Barrett; gastric adenocarcinoma (intestinal type) from H. pylori-driven intestinal metaplasia; squamous cell carcinoma from bronchial squamous metaplasia — dysplasia is the intermediate lesion, and progression is signalled on surveillance biopsy, not by symptoms.
• Loss of mucociliary clearance: squamous metaplasia strips cilia — recurrent bronchitis/pneumonia.
• Keratomalacia and corneal ulceration in untreated vitamin A deficiency — sight-threatening.

Treatment-related

• Post-ablation esophageal stricture, bleeding, perforation after radiofrequency ablation/EMR — new dysphagia or chest pain post-procedure.
• Finasteride lowers serum PSA by roughly half, masking prostate cancer if unadjusted; alpha-1 blockers cause orthostatic hypotension and intraoperative floppy iris syndrome; systemic high-dose progestins (e.g., megestrol) carry VTE risk, whereas the levonorgestrel IUS acts locally and is not associated with a comparable risk.

• Cell type dictates the adaptation: permanent cells (cardiac myocytes, neurons, skeletal muscle) can only hypertrophy; labile and stable cells (epithelium, liver, endometrium) can also hyperplase. A stem asking why a hypertensive heart enlarges without new myocytes is testing this.
• The uterus in pregnancy does both — myometrial hypertrophy and hyperplasia — the classic "both mechanisms" answer.
• Metaplasia is not dysplasia and not premalignant by itself; the risk comes from the persisting stimulus driving metaplasia → dysplasia → carcinoma. Intact basement membrane, orderly maturation, no atypia = metaplasia.
• Barrett esophagus = goblet cells / specialized intestinal metaplasia replacing distal squamous epithelium → adenocarcinoma. Contrast with mid-esophageal squamous cell carcinoma from smoking and alcohol. Best next step for new dysphagia or alarm features in chronic GERD: upper endoscopy with biopsy (ACG).
• BPH is hyperplasia of the transition/periurethral zone and is not a premalignant lesion; prostate adenocarcinoma arises in the peripheral zone. This is the single most-tested distractor in this topic.
• Lipofuscin is the "wear-and-tear" pigment of atrophy and aging — golden-brown, perinuclear, seen in brown atrophy of the heart and liver; it reflects lipid peroxidation of membranes, not iron (that's hemosiderin, Prussian blue positive).
• Grouped fiber atrophy on muscle biopsy = denervation (whole motor unit lost); scattered/type II fiber atrophy = disuse or glucocorticoid excess.
• Vitamin A deficiency → squamous metaplasia of respiratory, urinary and ocular epithelium with Bitot spots and night blindness; vitamin A is the differentiation signal for mucus-secreting epithelium.
• Athlete's heart vs HCM: physiologic hypertrophy is symmetric, regresses with detraining, and has normal diastolic function; myofiber disarray on histology and a dynamic outflow murmur point to HCM.
• Don't call the adaptation the disease — the exam wants the stimulus removed (BP control, PPI, H. pylori eradication, smoking cessation, progestin/hysterectomy) rather than treatment aimed at the histologic finding.